| Editor's Note: Fierce Biotech will be taking a break Thursday and Friday for the Thanksgiving Holiday. We'll be back in your inbox on Monday. |
Today’s Big NewsNov 27, 2024 |
|
Tuesday, December 3, 2024 | 11am ET / 8am PT Join us for a deep dive into the development and manufacturing of monoclonal antibodies. We’ll explore an industry case study, providing access to key findings, top strategies and solutions for enhancing productivity and efficiency in mAb production. Don’t miss out on important insights, register now.
|
|
| By Gabrielle Masson President-elect Donald Trump has chosen Stanford University’s Jay Bhattacharya, M.D., Ph.D., to serve as the director of the National Institutes of Health. |
|
|
|
By Nick Paul Taylor PTC Therapeutics’ amyotrophic lateral sclerosis prospect has flunked a phase 2 trial, prompting the biotech to drop plans for further development of the drug candidate. |
By Fraiser Kansteiner Kronos will lay off some 83% of its workforce by the end of the year as it continues to explore options to stay afloat, including “possible business combinations” or the divesture of remaining preclinical assets. Additionally, the company's CEO, Norbert Bischofberger, Ph.D., is stepping down from his post on Dec. 3. |
Sponsored by Questex Discover the trailblazers shaping the future of healthcare, biotech, and pharma at the Fierce 50 Awards Gala. |
|
Wednesday, December 4, 2024 | 11am ET / 8am PT Designing nanodevices that can change shape and function in response to molecular signals is a key objective in protein design, paving the way for the development of switchable nanomaterials, triggerable drug-delivery systems, and molecular motors. Join us for a deep dive into the recent progress in designing and characterizing a diverse range of switchable protein assemblies. Register now.
|
|
By James Waldron Idorsia may have negotiated a $35 million payday ahead of a potential licensing deal for its hypertension drug Tryvio, but that won’t be enough to save the 270 roles the company is looking to cut. |
By James Waldron PTC Therapeutics may be reeling from the failure of its amyotrophic lateral sclerosis drug yesterday, but the biotech can console itself by counting the cash from the sale of its priority review voucher. |
By Nick Paul Taylor Outlook Therapeutics’ eye disease drug has failed to match Roche’s Lucentis in a key trial. The biotech brushed off the failure, noting positive details and vowing to seek FDA approval, but investors were less sanguine about the setback. |
By Gabrielle Masson Acadia Pharmaceuticals has penned an exclusive licensing deal worth up to $582 million biobucks for Saniona’s neurological disorder asset. |
By Darren Incorvaia The academic-led, industry-partnered collaboration Equitable Breakthroughs in Medicine Development has released an assessment tool for clinical trial sites to evaluate their ability to perform diverse trials and chart out a path toward improvement in health equity. |
By Kevin Dunleavy A survey of life sciences CEOs found that 94% plan to grow their workforce over the next three years, with 37% envisioning that the head count of their company will grow by at least 6%. The results back up the confidence the CEOs have in their companies’ growth prospects. |
By Zoey Becker The treatment, which was once a Pfizer antidepressant, reduced bouts of cataplexy and other narcolepsy symptoms in Axsome's ENCORE study. |
By Conor Hale The company said it would allow severely paralyzed patients currently signed up to receive the implant through its PRIME safety trial to also cross-enroll in a new study, named CONVOY. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," Fierce editors discuss our special report celebrating 10 women driving change in clinical research, business development, venture capital, and more |
|
|---|
|
|
|
Tuesday, December 10, 2024 | 12pm ET / 9am PT Mammalian synthetic biology has shown that key principles of biological regulation can be rewritten to control gene expression and produce complex, cellular behaviors. Recently, these core principles have now been applied at the protein level. Join us to learn about these latest approaches, and what the mean for cancer biology, immunology, and neuroscience. Sign up now!
|
|
| WhitepaperExplore the robust cross-platform agreement between scRNA-seq and bulk RNA-seq, ensuring consistent and reproducible data on immune cell presence. Sponsored by: IQVIA Laboratories |
| WhitepaperThe use of prefilled syringes to administer biotherapeutics is beginning to gain traction because they offer a range of stability, efficacy, and patient safety benefits. Download this white paper to learn how Lonza has developed a novel workflow to ensure confidence regarding functionality in PFS and autoinjectors. Presented by Lonza |
| WhitepaperThis e-book explores 7 factors that are critical to the success of emerging biopharma companies, whether they plan to out-license, partner, or launch & commercialize products. It’s an essential resource for emerging companies with products in all stages of development. Sponsored by: Blue Matter |
| WhitepaperLearn how to evaluate quality documentation to help you select the right raw materials at early decision points for your cell-based manufacturing processes. Presented by: Thermo Fisher Scientific |
On Helix Date: 4 July 2024 - Location: Babraham Research Campus, Cambridge UK |
|
| |
|
